BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...

RESEARCHERS from SINTEF have developed a “simpler” low-cost carbon capture and storage (CCS) system for sequestering ...

BioNTech inks a deal to acquire Biotheus and gain full global rights to a bispecific antibody, BNT327/PM8002, being studied for various oncology indications.

BioNTech SE and Biotheus (Biotheus) announced the signing of a definitive agreement for the acquisition of Biotheus, a clinical-stage biotechnology company dedicated to the discovery and development ...

BioNTech, the German developer of a widely used mRNA vaccine for the coronavirus, agreed to pay US$800 million (HK$6.24 billion) to buy biotech company Biotheus, a developer of cancer drugs. In a ...

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Instil Bio (TIL – Research Report) today and set a price target of ...

H.C. Wainwright lowered the firm’s price target on Instil Bio (TIL) to $110 from $120 and keeps a Buy rating on the shares post the Q3 ...

Summit and Akeso's ivonescimab attracted headlines earlier this year when it was shown to be more effective than anti-PD-1 ...

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.

This class of drug has been attracting increased interest for deals. On Wednesday, German drugmaker BioNTech said it would ...

Vaccine maker shares closed lower Thursday amid reports that Donald Trump was set to nominate vaccine critic Robert F.

The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...